Literature DB >> 22507357

Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.

Yuki Kagoya1, Sachiko Seo, Yasuhito Nannya, Mineo Kurokawa.   

Abstract

Hyperlipidemia is one of the late complications after allogeneic stem cell transplantation (SCT). Although intrahepatic cholestasis caused by chronic graft-versus-host disease (GVHD) or calcineurin inhibitors has been considered as possible etiologies, its prevalence, risk factors, and impact on prognosis have not been investigated well. We performed a retrospective analysis of 194 patients who underwent allogeneic SCT between 1995 and 2008 in our institute and survived more than 100 d after SCT. Overall, 83 (42.8%) and 99 (50.8%) patients developed hypercholesterolemia (≥240 mg/dL) and hypertriglyceridemia (≥200 mg/dL), respectively. In multivariate analysis, the development of chronic GVHD (hazard ratio [HR] 2.04, p < 0.05) and steroid use (HR 2.24, p < 0.01) were independently associated with hypercholesterolemia, while administration of calcineurin inhibitors was not. As for the prognostic impact, multivariate analysis showed that the patients with hypercholesterolemia had a tendency of lower rate of relapse (HR: 0.44, p = 0.07). There was no difference in non-relapse mortality or overall survival between the groups. In conclusion, the development of hypercholesterolemia is regarded as one of the symptoms accompanied with chronic GVHD and might indicate a better control of the primary disease.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22507357     DOI: 10.1111/j.1399-0012.2012.01628.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  10 in total

1.  Endocrine Challenges and Metabolic Profile in Recipients of Allogeneic Haematopoietic Stem Cell Transplant: A Cross-Sectional Study from Southern India.

Authors:  Kripa Elizabeth Cherian; Nitin Kapoor; Anup J Devasia; Vikram Mathews; Alok Srivastava; Nihal Thomas; Biju George; Thomas V Paul
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-16       Impact factor: 0.900

Review 2.  Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients.

Authors:  Bernard Lawrence Marini; Sung Won Choi; Craig Alan Byersdorfer; Simon Cronin; David G Frame
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

3.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.

Authors:  Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-30       Impact factor: 5.742

Review 4.  Long-term follow-up after allogeneic stem cell transplantation.

Authors:  Inken Hilgendorf; Hildegard Greinix; Jörg P Halter; Anita Lawitschka; Hartmut Bertz; Daniel Wolff
Journal:  Dtsch Arztebl Int       Date:  2015-01-23       Impact factor: 5.594

Review 5.  Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT.

Authors:  Z DeFilipp; R F Duarte; J A Snowden; N S Majhail; D M Greenfield; J L Miranda; M Arat; K S Baker; L J Burns; C N Duncan; M Gilleece; G A Hale; M Hamadani; B K Hamilton; W J Hogan; J W Hsu; Y Inamoto; R T Kamble; M T Lupo-Stanghellini; A K Malone; P McCarthy; M Mohty; M Norkin; P Paplham; M Ramanathan; J M Richart; N Salooja; H C Schouten; H Schoemans; A Seber; A Steinberg; B M Wirk; W A Wood; M Battiwalla; M E D Flowers; B N Savani; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2016-08-22       Impact factor: 5.483

Review 6.  Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues.

Authors:  Roshni Bhatnagar; Neal M Dixit; Eric H Yang; Tamer Sallam
Journal:  Front Cardiovasc Med       Date:  2022-08-09

Review 7.  Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Yingxue Lu; Xiaojing Ma; Jie Pan; Rongqiang Ma; Yujie Jiang
Journal:  Lipids Health Dis       Date:  2022-08-02       Impact factor: 4.315

Review 8.  Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons.

Authors:  Mehdi Mohammadi; Mohammad Vaezi; Bahador Mirrahimi; Molouk Hadjibabaie
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-01-01

9.  Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT.

Authors:  Zachariah DeFilipp; Rafael F Duarte; John A Snowden; Navneet S Majhail; Diana M Greenfield; José López Miranda; Mutlu Arat; K Scott Baker; Linda J Burns; Christine N Duncan; Maria Gilleece; Gregory A Hale; Mehdi Hamadani; Betty K Hamilton; William J Hogan; Jack W Hsu; Yoshihiro Inamoto; Rammurti T Kamble; Maria Teresa Lupo-Stanghellini; Adriana K Malone; Philip McCarthy; Mohamad Mohty; Maxim Norkin; Pamela Paplham; Muthalagu Ramanathan; John M Richart; Nina Salooja; Harry C Schouten; Helene Schoemans; Adriana Seber; Amir Steinberg; Baldeep M Wirk; William A Wood; Minoo Battiwalla; Mary E D Flowers; Bipin N Savani; Bronwen E Shaw
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-14       Impact factor: 5.742

10.  Confirmation of the abnormal lipid metabolism as a risk factor for the disease of leukoaraiosis.

Authors:  Junying Shi; Kai Hao; Peihong Qi; Xiaogang Xie; Xinhuan Yang; Mei Dong; Yingjie Shang; Sijia Zhang
Journal:  Saudi J Biol Sci       Date:  2017-01-26       Impact factor: 4.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.